SCHEMBL5952446

SCHEMBL5952446

Cc1cc(N)c(N)cc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.52
PDE4B Q07343 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
PDE3B Q13370 1/20 0.52
PDE3A Q14432 1/20 0.52
ALDH1A1 P00352 5/20 0.50
HSD17B10 Q99714 4/20 0.50
ESR2 Q92731 1/20 0.50
DHFR P00374 1/20 0.50
CYP2A6 P11509 1/20 0.43
CYP2B6 P20813 1/20 0.43
CYP3A4 P08684 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
BACE1 P56817 1/20 0.41
SMARCA2 P51531 2/20 0.41
SMARCA4 P51532 2/20 0.41
PBRM1 Q86U86 2/20 0.41
PKM P14618 1/20 0.41
TDO2 P48775 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27635537 0.89 DHFR (0.49) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL6572093 0.84 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL7649793 0.83 ALDH1A1 (0.62) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL4830408 0.83 ESR2 (0.60) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL30594664 0.83 ALDH1A1 (0.62) PDE4APDE4BPDE4CPDE4DPDE3B
Hydrochloric Acid SCHEMBL6570955 0.83 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL656285 0.81 ALDH1A1 (0.46) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL656284 0.81 ALDH1A1 (0.46) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL5547251 0.80 ESR2 (0.58) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL12117487 0.79 IDO1 (0.53) PDE4APDE4BPDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242512-A1 ISOINDOLINES AS HDAC INHIBITORS VALO HEALTH, INC. 2023-08-03 US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 PDE4A 668/4885PDE4B 579/4885PDE4C 692/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A PDE4A 887/4885PDE4B 868/4885PDE4C 967/4885
US-20230242512-A1 ISOINDOLINES AS HDAC INHIBITORS HDAC1, HDAC2, HDAC3 PDE4A 2660/4885PDE4B 2930/4885PDE4C 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.